ARVIDAL

Class [005]
Pharmaceutical preparations, in the nature of anti-viral agents, interferon-inducing agents for enhancing the immune system, and Pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections or diseases caused by viruses, namely respiratory infections, diseases and disorders; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections or diseases caused by viruses, namely by intravenous fluids used for the delivery of pharmaceutical preparations, intramuscular injection, oral spray preparations, sublingual doses, buccal swabs for medical use, nasal spray preparations, topical anti-inflammatories and administered by inhalation, by spraying or by nebulisation in patients all for the treatment of viral respiratory infections, diseases and disorders; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections caused by viruses, namely respiratory infections, seasonal and pandemic influenza A and B viruses, seasonal coronaviruses (Alpha-, Beta-, Gamma- and Deltacoronaviruses), severe acute respiratory syndrome (SARS-CoV) coronaviruses and Middle East respiratory syndrome (MERS) coronavirus, adenoviruses, respiratory syncytial viruses, parainfluenza viruses, rhinoviruses, human metapneumoviruses, bocaviruses, and infections of combined etiology (multiple viral infections); pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections caused by viral infections of the upper and lower respiratory tract; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of acute respiratory infections caused by viral infections of the upper and lower respiratory tract; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of tissue lesions in the lungs caused by severe pulmonary infectious diseases; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of complications arising from or caused by respiratory viral infections, namely lung damage, viral pneumonia and cytokine storms; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of acute respiratory infections, acute respiratory viral infections of unknown origins and complications arising from or caused by viral infections.